FDA Approval Won't Make Stem Cell Therapy Cheaper | #195

FDA Approval Won't Make Stem Cell Therapy Cheaper | #195

What insights can experts and survivors share about addiction? Here, the focus shifts to another kind of struggle: the gap between expectations and reality in stem cell therapy costs. The episode centres on Dr. Joy Kong, a triple board-certified physician and stem cell specialist, as she gives a clear, numbers-based explanation of why waiting for FDA approval may not make stem cell therapy cheaper. You’ll hear Dr. Kong walk through the hard figures behind FDA-approved stem cell products.

She explains that in 2026 it cost between $2 billion and $2.6 billion for a drug company to bring a single drug to market, adding, "Don't you think they're going to want to recover that cost? And where is that going to come from, right?

From you?" From there, she breaks down real pricing examples: umbilical cord blood products like Allocord and Omidubicel, which can range from hundreds of thousands to over a million dollars once hospital stays, chemotherapy, and follow-up care are included. Dr. Kong then contrasts these eye-watering figures with legally provided stem cell tissue transplants in clinical practice, which typically cost between $7,000 and $25,000 per IV infusion.

She explains how these procedures fall under tissue transplant rules rather than drug approval, comparing them to organ transplants done by licensed physicians, and notes that she has trained hundreds of doctors to offer this kind of therapy safely. The style is straightforward and factual, aimed at people curious about stem cell therapy, longevity medicine, or anti-ageing treatments who may be assuming that FDA approval will bring prices down or automatically unlock insurance coverage.

Instead of hype, you’ll get a calm reality check and a detailed look at what current costs really mean. If you’ve been pinning your hopes on FDA approval making stem cell therapy cheap, this episode might prompt you to rethink your assumptions and look more closely at the options already available.